Overview

Terazosin for Parkinson's Disease

Status:
Completed
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jordan Schultz
Collaborators:
University of Iowa
University of Iowa Institute of Clinical and Translational Sciences
Treatments:
Prazosin
Terazosin